Table 2 Predictors of abatacept discontinuation. Cox regression analysis
Unadjusted analysis HR (95% CI) | Multivariate analysis—final model HR (95% CI) | |
|---|---|---|
Sex | ||
Male | 0.85 (0.75–0.96) | 0.86 (0.74–0.98) |
No of previous bDMARDs | ||
≥ 2 bDMARDs | Reference (1.0) | * |
Bionaïve | 0.78 (0.68–0.90) | * |
1 bDMARD | 0.94 (0.84–1.05) | * |
Baseline clinical characteristics | ||
DAS28-CRP (per SD) | 1.11 (1.04–1.17) | * |
VAS pain (per SD) | 1.14 (1.08–1.21) | 1.14 (1.07–1.20) |
Current Methotrexate | 0.86 (0.78–0.96) | 0.85 (0.76–0.95) |
HAQ-DI (per SD) | 1.10 (1.04–1.17) | * |
Age (per SD) | 0.99 (0.94–1.04) | * |
Disease duration (per SD) | 0.98 (0.93–1.03) | * |
Current glucocorticoids | 1.08 (0.98–1.19) | * |
Current csDMARD | 0.93 (0.85–1.03) | * |
i.v. abatacept administration | 1.02 (0.92–1.12) | * |